ALS Investment Fund is a venture capital fund managed by SUNU Ventures that invests in biotech companies developing drugs and diagnostics for neurodegenerative diseases, with a particular focus on ALS. Based in Amsterdam, the fund backs early-stage companies entering proof-of-concept and Phase 1/2 clinical investigations.
33% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (50% of deals). Average disclosed round size is $91.0M (across 5 rounds with reported amounts).
Portfolio
5
Fund Size
$100M
Top Stage
Series A
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| VVectorY Therapeutics | Series A | $138M | Nov 2023 |
| QQualis Corporation | Series B | $88M | Mar 2023 |
| VVectorY Therapeutics | Series A | $129M | Jan 2023 |
 Bloom Science | Series A | $12M | Dec 2021 |
 Emulate | Series C | — | Jun 2018 |
 QurAlis | Series B | $88M | — |
Top Co-Investors
EQT Life Sciences4 shared
Sanofi Ventures2 shared
Dolby Family Ventures2 shared
Dementia Discovery Fund2 shared
Amgen Ventures2 shared
Mission BioCapital2 shared
INKEF Capital2 shared
MRL Ventures Fund2 shared
BioGeneration Ventures2 shared
Forbion2 shared
Insight Partners2 shared
Leaps by Bayer1 shared
Apollo Health Ventures1 shared
Joyance Partners1 shared
Polaris Innovation Fund1 shared
PACE Healthcare Capital1 shared
Adara Ventures1 shared
SciFi VC1 shared
Founders Fund1 shared
Last updated: 8 September 2026